The University of Chicago Header Logo

Connection

Seiko Diane Yamada to Prognosis

This is a "connection" page, showing publications Seiko Diane Yamada has written about Prognosis.
Connection Strength

0.163
  1. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.
    View in: PubMed
    Score: 0.062
  2. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.025
  3. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
    View in: PubMed
    Score: 0.024
  4. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
    View in: PubMed
    Score: 0.013
  5. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.
    View in: PubMed
    Score: 0.012
  6. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.011
  7. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5546-53.
    View in: PubMed
    Score: 0.009
  8. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.